How an unproven drug became a bellwether for global stocks
Is the antiviral medication remdesivir the solution investors have been looking for? "The positive data from the remdesivir study run by the US government was accompanied by several caveats. Dr Fauci warned it was not a "knockout" trial and that the drug did not demonstrate a statistically significant impact on survival rates. Researchers say it is impossible to draw firm conclusions without first seeing the full results, which have yet to be published in a medical journal." David Crow, Hannah Kuchler and Eric Platt investigate in the Financial Times.
From Financial Times